Staging in patients with locoregionally recurrent breast cancer: Current practice and prospects for positron emission tomography

European Journal of Cancer

Volumn 40, Issue 10, 2004, Pages 1545-1553

  Van Oost, F J ^a   Van Der Hoeven, J J M ^b,c   Hoekstra, O S ^c   Voogd, A C ^a,d   Coebergh, J W W ^a,e   Van De Poll Franse, L V ^a  

^a Eindhoven Cancer Registry   (Netherlands)

^b AMSTELLAND HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

2 Fluoro 2 deoxy D glucose; Breast cancer; PET; Positron emission tomography; Recurrence; Staging

Indexed keywords

ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER STAGING; CLINICAL PRACTICE; HEALTH CARE POLICY; HUMAN; IMAGING; MEDICAL RECORD; METASTASIS; NETHERLANDS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUESTIONNAIRES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2942576059     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.03.012     Document Type: Article

References (40)

1. Voogd A.C., Nielsen M., Peterse J.L., et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J. Clin. Oncol. 19:2001;1688-1697
2. Veronesi U., Marubini E., Del Vecchio M., et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J. Natl. Cancer Inst. 87:1995;19-27
3. Fisher B., Anderson S., Fisher E.R., et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 338:1991;327-331
4. Elkhuizen P.H., van de Vijver M.J., Hermans J., Zonderland H.M., van de Velde C.J., Leer J.W. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;859-867
5. Samant R., Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch. Surg. 134:1999;551-553. discussion 554
6. Ravaioli A., Tassinari D., Panzini I., Milandri C., Amadori D. Staging of breast cancer: it is time to break with tradition and initiate the evidence-based-medicine age. J. Clin. Oncol. 19:2001;1234
7. Yeh K.A., Fortunato L., Ridge J.A., Hoffman J.P., Eisenberg B.L., Sigurdson E.R. Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann. Surg. Oncol. 2:1995;319-324
8. Chen E.A., Carlson G.A., Coughlin B.F., Reed W.P., Jr J.L., Garb J.L. Routine chest roentgenography is unnecessary in the work-up of stage I and II breast cancer. J. Clin. Oncol. 18:2000;3503-3506
9. Barry M.C., Thornton F., Murphy M., Younis F., Watson R.G. The value of metastatic screening in early primary breast cancer. Ir. J. Med. Sci. 168:1999;248-250
10. Comans E.F., Hoekstra O.S., Hoekman K., van der Hoeven J.J., Golding R.P., Teule G.J. Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology. Ned. Tijdschr. Geneeskd. 144:2000;1520-1528
11. Bender H., Kirst J., Palmedo H., et al. Value of fluoro-18-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 17:1997;1687-1692
12. Cook G.J., Houston S., Rubens R., Maisey M.N., Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J. Clin. Oncol. 16:1998;3375-3379
13. Dose J., Bleckmann C., Bachmann S., et al. Comparison of fluorodeoxyglucose positron emission tomography and 'conventional diagnostic procedures' for the detection of distant metastases in breast cancer patients. Nucl. Med. Commun. 23:2002;857-864
14. Eubank W.B., Mankoff D.A., Vesselle H.J., et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics. 22:2002;5-17
15. Hubner K.F., Smith G.T., Thie J.A., Bell J.L., Nelson H.S., Hanna W.T. The potential of F-18-FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin. Positron Imaging. 3:2000;197-205
16. Kim T.S., Moon W.K., Lee D.S., et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J. Surg. 25:2001;829-834
17. Lonneux M., Borbath I.I., Berliere M., Kirkove C., Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin. Positron Imaging. 3:2000;45-49
18. Moon D.H., Maddahi J., Silverman D.H.S., Glaspy J.A., Phelps M.E., Hoh C.K. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J. Nucl. Med. 39:1998;431-435
19. Schirrmeister H., Kuhn T., Guhlmann A., et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur. J. Nucl. Med. 28:2001;351-358
20. Yap C.S., Seltzer M.A., Schiepers C., et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J. Nucl. Med. 42:2001;1334-1337
21. Herder G.J., Verboom P., Smit E.F., et al. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax. 57:2002;11-14
22. Voogd A.C., van Beek M.W., Crommelin M.A., Kluck H.M., Repelaer van Driel O.J., Coebergh J.W. Management of early breast cancer in southeast Netherlands since 1984. A population-based study. Regional Breast Cancer Study Group. Acta Oncol. 33:1994;753-757
23. Voogd A.C., van Tienhoven G., Peterse H.L., et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Cancer. 85:1999;437-446
24. Antoch G., Vogt F.M., Freudenberg L.S., et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama. 290:2003;3199-3206
25. Adler L.P., Crowe J.P., al-Kaisi N.K., Sunshine J.L. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology. 187:1993;743-750
26. Greco M., Crippa F., Agresti R., et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J. Natl. Cancer Inst. 93:2001;630-635
27. Noh D.Y., Yun I.J., Kim J.S., et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J. Surg. 22:1998;223-227. discussion 227-8
28. van der Hoeven J.J., Hoekstra O.S., Comans E.F., et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann. Surg. 236:2002;619-624
29. Yang S.N., Liang J.A., Lin F.J., Kao C.H., Lin C.C., Lee C.C. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J. Cancer Res. Clin. Oncol. 128:2002;325-328
30. Avril N., Dose J., Janicke F., et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J. Clin. Oncol. 14:1996;1848-1857
31. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur. J. Nucl. Med. 23:1996;618-623
32. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J. Clin. Oncol. 18:2000;3495-3502
33. Li C.I., Anderson B.O., Daling J.R., Moe R.E. Trends in incidence rates of invasive lobular and ductal breast carcinoma. Jama. 289:2003;1421-1424
34. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur. J. Nucl. Med. 25:1998;1429-1434
35. Avril N., Menzel M., Dose J., et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J. Nucl. Med. 42:2001;9-16
36. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl. Med. Commun. 22:2001;875-879
37. Suarez M., Perez-Castejon M.J., Jimenez A., et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q. J. Nucl. Med. 46:2002;113-121
38. van der Hoeven J.J., Krak N.C., Hoekstra O.S., et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J. Clin. Oncol. 22:2004;1253-1259
39. 18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer. 39:2003;151-157
40. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:2002;1999-2009